HK1204473A1 - 製造和使用納米結構的方法 - Google Patents
製造和使用納米結構的方法Info
- Publication number
- HK1204473A1 HK1204473A1 HK15105001.9A HK15105001A HK1204473A1 HK 1204473 A1 HK1204473 A1 HK 1204473A1 HK 15105001 A HK15105001 A HK 15105001A HK 1204473 A1 HK1204473 A1 HK 1204473A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- nanostructures
- making
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261588621P | 2012-01-19 | 2012-01-19 | |
US201261595531P | 2012-02-06 | 2012-02-06 | |
US201261695775P | 2012-08-31 | 2012-08-31 | |
PCT/US2013/022218 WO2013109939A1 (en) | 2012-01-19 | 2013-01-18 | Methods of making and using nanostructures |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1204473A1 true HK1204473A1 (zh) | 2015-11-20 |
Family
ID=47630584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15105001.9A HK1204473A1 (zh) | 2012-01-19 | 2015-05-26 | 製造和使用納米結構的方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US9486535B2 (zh) |
EP (1) | EP2804862B1 (zh) |
HK (1) | HK1204473A1 (zh) |
WO (1) | WO2013109939A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9499800B2 (en) | 2013-12-26 | 2016-11-22 | Regents Of The University Of Minnesota | Methods of making and using chemically self assembled-nanorings |
US10239891B2 (en) * | 2017-05-15 | 2019-03-26 | Indicator Systems International, Inc. | Compositions to detect remnant cancer cells |
EP3493855A4 (en) | 2016-08-02 | 2020-04-01 | ISI Life Sciences, Inc. | METHOD FOR DETECTION OF CANCER CELLS. |
CN106831491A (zh) * | 2016-12-29 | 2017-06-13 | 苏州昊帆生物股份有限公司 | 2‑(2‑(2‑氨基乙氧基)乙氧基)乙基氨基甲酸叔丁酯的制备方法 |
US10753942B2 (en) | 2017-05-15 | 2020-08-25 | Indicator Systems International, Inc. | Methods to detect remnant cancer cells |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA120116A (en) | 1909-03-29 | 1909-08-24 | William H. Bantly | Support for shades and curtains |
CA125360A (en) | 1909-12-01 | 1910-04-26 | Charles W. Stark | Fastener |
US4612302A (en) | 1983-11-14 | 1986-09-16 | Brigham And Women's Hospital | Clinical use of somatostatin analogues |
US4684620A (en) | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
US4853371A (en) | 1986-06-17 | 1989-08-01 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
CA2379375A1 (en) | 2002-03-28 | 2003-09-28 | Apotex Inc. | Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases |
US8236925B1 (en) | 2005-08-26 | 2012-08-07 | University Of Minnesota | Protein nanorings |
WO2011059586A2 (en) * | 2009-10-30 | 2011-05-19 | The Regents Of The University Of Michigan | Multifunctional small molecules |
-
2013
- 2013-01-18 WO PCT/US2013/022218 patent/WO2013109939A1/en active Application Filing
- 2013-01-18 US US14/373,209 patent/US9486535B2/en active Active
- 2013-01-18 EP EP13702171.3A patent/EP2804862B1/en active Active
-
2015
- 2015-05-26 HK HK15105001.9A patent/HK1204473A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2013109939A1 (en) | 2013-07-25 |
EP2804862A1 (en) | 2014-11-26 |
US20150017189A1 (en) | 2015-01-15 |
EP2804862B1 (en) | 2019-07-17 |
US9486535B2 (en) | 2016-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181628T1 (hr) | Spojevi i postupci za njihovu upotrebu | |
HK1212256A1 (zh) | 抗- 抗體及相關使用方法 | |
HK1208439A1 (zh) | -氮雜吲唑化合物及其使用方法 | |
EP2912178A4 (en) | SUPER AMPLIFIER AND METHOD FOR USE THEREOF | |
EP2867156A4 (en) | HIGH LUMINESCENT NANOSTRUCTURES AND METHOD FOR THE PRODUCTION THEREOF | |
IL238227A0 (en) | Antibodies against c16orf54 and uses thereof | |
EP2844903A4 (en) | TUBES AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
ZA201404675B (en) | Anti-lrp5 antibodies and methods of use | |
EP2938632A4 (en) | ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE | |
EP2928900A4 (en) | GUANIDIN-FUNCTIONALIZED PARTICLES AND METHOD OF PREPARATION AND USE | |
EP2852397A4 (en) | HUWENTOXIN IV VARIANTS AND METHODS OF USE | |
HK1209432A1 (zh) | 抗鋸齒蛋白抗體及使用方法 | |
EP2919983A4 (en) | ARTICLES WITH FIBER-REINFORCED POLYMERS AND METHOD OF USE THEREOF | |
EP2844364A4 (en) | SEALED SEAM FILTER AND METHOD OF MANUFACTURING THEREOF | |
EP2888227A4 (en) | NEW PRODRUGS AND METHODS OF USE | |
HK1204473A1 (zh) | 製造和使用納米結構的方法 | |
EP2670245A4 (en) | ALPHA-CÉTOHÉTÉROCYCLES AND METHODS OF MAKING AND USING THEM | |
GB2509246B (en) | Component and method of formation thereof | |
EP2909145A4 (en) | METHODS OF REDUCING TARTER FORMATION | |
EP2837624A4 (en) | 4-SUBSTITUTE-2-HYDROXYLMORPHOLIN-3-ON AND METHOD OF MANUFACTURING THEREOF | |
PL2864417T3 (pl) | Polimer i sposób zastosowania | |
ZA201408128B (en) | Etract of greyia radlkoferi and use thereof | |
ZA201405644B (en) | Weatherised minerals and methods of making and using same | |
GB201213778D0 (en) | Process and dressng | |
GB201316230D0 (en) | Catalysts and methods of making and using catalysts |